Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Chief Medical Officer | April 22, 2020 | April 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date April 22, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2028-08-15 | Direct | 0 |
Reported balance
After 2020-04-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-22 · Disposition to issuer · Disposed 208,216 · Balance 0 F2: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.45 · Expires 2028-08-15 | Direct | 208,216 |
Reported balance
After 2020-04-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-22 · Grant · Acquired 208,216 · Balance 208,216 F2: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.16 · Expires 2029-02-12 | Direct | 0 |
Reported balance
After 2020-04-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-22 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.45 · Expires 2029-02-12 | Direct | 90,000 |
Reported balance
After 2020-04-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-22 · Grant · Acquired 90,000 · Balance 90,000 F3: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.75 · Expires 2029-12-09 | Direct | 0 |
Reported balance
After 2020-04-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-22 · Disposition to issuer · Disposed 125,000 · Balance 0 F4: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.45 · Expires 2029-12-09 | Direct | 125,000 |
Reported balance
After 2020-04-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-22 · Grant · Acquired 125,000 · Balance 125,000 F4: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
F2: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.
F3: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.
F4: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Frazier Lifesciences Acquisition Corp
Report date November 22, 2022 · Filed November 23, 2022
Section 16 reporting ended · disclosed 2022-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-22 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.
Raptor Pharmaceutical Corp
Report date October 24, 2016 · Filed October 26, 2016
Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 1
1 source rowRow 1 · 2016-10-25 · Disposition to issuer · Disposed 23,781 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of September 12, 2016, by and among Raptor Pharmaceutical Corp., Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (the "Merger Agreement"), on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. |
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2026-02-09 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-25 · Disposition to issuer · Disposed 89,152 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of September 12, 2016, by and among Raptor Pharmaceutical Corp., Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (the "Merger Agreement"), on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 22, 2022 Filed Nov 23, 2022 16:25 UTC | Frazier Lifesciences Acquisition Corp FLAC · Entity 122080 | Exercise / conversionClass B Ordinary Shares · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-036925 · doc4.xml · derivative · entry 1 Polu Krishna R · CIK 0001630996 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · price: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · derivative.exercise_date: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · derivative.expiration_date: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025656 · doc4.xml · derivative · entry 6 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-12-09 F4 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001209191-20-025656 · doc4.xml · derivative · entry 5 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2029-12-09 F4 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025656 · doc4.xml · derivative · entry 4 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-02-12 F3 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $7.16 | Not disclosed |
DisclosureSEC source: 0001209191-20-025656 · doc4.xml · derivative · entry 3 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-02-12 F3 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 208,216 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025656 · doc4.xml · derivative · entry 2 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,216 Underlying: Common Stock · 208,216 shares Expires 2028-08-15 F2 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 208,216 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001209191-20-025656 · doc4.xml · derivative · entry 1 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 208,216 shares Expires 2028-08-15 F2 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 17:54 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-060268 · doc4.xml · derivative · entry 1 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-12-09 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 18:21 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001209191-19-010766 · doc4.xml · derivative · entry 1 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-02-12 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:35 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerStock Option(right to buy) · Derivative | 89,152 | Not disclosed Strike: $3.74 | Not disclosed |
DisclosureSEC source: 0001140361-16-083643 · doc1.xml · derivative · entry 2 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,152 shares Expires 2026-02-09 F2 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:35 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerCommon Stock | 23,781 | $9.00 | $214,029.00 |
DisclosureSEC source: 0001140361-16-083643 · doc1.xml · nonDerivative · entry 1 Polu Krishna R · CIK 0001630996 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger dated as of September 12, 2016, by and among Raptor Pharmaceutical Corp., Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (the "Merger Agreement"), on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.